Resources - MECHANISMS
Retatrutide dosage, how it is taken and side effects: what the trials actually show
Retatrutide is an experimental weekly injection studied at 0.5 to 12 mg across two phase 2 trials. What doses the studies used, how the dose was increased, the weight loss reported, the side effects recorded, and why none of it is a personal dosing guide.
Retatrutide is an experimental weekly injection that acts on three hormone receptors at once, and in the trials published so far it has been given at doses between 1 mg and 12 mg a week, stepped up gradually over the first weeks. It is not licensed anywhere, so there is no routine prescribing route to it in the UK outside a clinical trial, and the only people who have taken it under any kind of medical oversight are trial participants. This article sets out what those trials used, how the drug was given, what weight change and side effects were recorded, and how strong that evidence is. It is written for people who have searched for retatrutide dosage or how to take it and want the actual data rather than a forum post. It is not a guide to taking anything. Nobody outside a trial can currently take retatrutide with any assurance of what is in the vial.
What retatrutide is and why the dose matters
Retatrutide is a single molecule engineered to activate three receptors that regulate appetite, blood sugar and energy use: the GLP-1 receptor, the GIP receptor and the glucagon receptor. Semaglutide acts on the first of those, tirzepatide on the first two; retatrutide adds the third. It is being developed by Eli Lilly, and its phase 2 results, published in 2023, reported among the largest average weight losses seen in phase 2 trials of this class, which is why it attracts so much attention while still years from a licence.
Dose matters with these drugs more than with most, for two reasons that pull in opposite directions. Effect rises with dose across the whole range tested, so the 12 mg groups lost far more weight than the 1 mg group. Side effects also rise with dose, especially the stomach and gut effects that make people stop. Trials in this class have therefore used escalating schedules, increasing the dose in steps over weeks and then holding a maintenance dose. Any dosing figure only makes sense read against the schedule it sat in.
The doses the phase 2 obesity trial actually used
The trial most people are quoting when they talk about retatrutide dosage is the phase 2 obesity study by Jastreboff and colleagues, published in the New England Journal of Medicine in 2023. It enrolled 338 adults with a body-mass index of 30 or more, or 27 or more with at least one weight-related condition, and excluded people with diabetes. Participants were randomised to placebo or to one of several retatrutide groups and followed for 48 weeks.
- 1 mg once weekly, taken at that dose from the start.
- 4 mg once weekly as the maintenance dose, reached either by starting at 2 mg and stepping up, or by starting at 4 mg.
- 8 mg once weekly as the maintenance dose, reached by starting at 2 mg or at 4 mg and stepping up.
- 12 mg once weekly as the maintenance dose, reached by starting at 2 mg and stepping up.
Step-ups happened at four-week intervals. Participants assigned to the higher maintenance doses reached them in steps rather than starting there, and then stayed at that dose for the remainder of the 48 weeks. The trial deliberately compared different starting doses for the same maintenance dose, to see whether a gentler start reduced side effects without costing effect. The lower starting dose was associated with fewer early gastrointestinal events and slightly smaller weight loss at 48 weeks.
Two things about these numbers are easy to miss. First, the doses are fixed milligram amounts for everyone in a group; nothing was calculated per kilogram of body weight. Second, "12 mg" describes the top of a 48-week programme, not a starting point. A figure quoted on its own, without the schedule it sat in, has lost most of its meaning.
The type 2 diabetes trial used a wider range
A parallel phase 2 trial in people with type 2 diabetes, led by Rosenstock and published in the Lancet in 2023, tested retatrutide from 0.5 mg up to 12 mg weekly over 36 weeks, against both placebo and a licensed comparator. It found dose-related reductions in blood sugar and body weight, with the same gastrointestinal side-effect profile. It matters here for one reason: it shows that the "right" dose depends on who is being treated and for what. The diabetes trial included a 0.5 mg dose that was not tested in the obesity trial. There is no single retatrutide dose; there are dose ranges chosen for particular populations and outcomes.
How retatrutide was taken in the trials
Once a week, as a subcutaneous injection, using a pre-filled injection device supplied by the manufacturer and set to deliver the trial dose. Participants were trained by study staff, injected on the same day each week, and were reviewed regularly, with blood tests, weight, blood pressure and heart rate recorded throughout. Anyone with a worrying result was assessed and, where needed, taken off the drug.
That context is the part that falls away when "how to take retatrutide" becomes a search query. The weekly injection is the visible bit. The invisible bits are the pharmaceutical-grade product of known content, the device calibrated to the dose, the escalation schedule written by the people who designed the molecule, and the monitoring that caught problems. None of those exist for a vial bought online. This is the reason a research-literacy site can describe how a trial worked and still not be describing how anyone should take anything.
Weight loss reported at each dose
At 48 weeks in the obesity trial, the average percentage change in body weight was roughly 8.7% in the 1 mg group, 17.1% at 4 mg, 22.8% at 8 mg and 24.2% at 12 mg, compared with about 2.1% in the placebo group. Almost everyone on the two highest doses lost at least 5% of their body weight, and the majority of those on 12 mg had lost 15% or more. In the higher-dose groups the weight curves had not flattened by 48 weeks, meaning the trial ended before the full effect was seen.
Read those figures with three caveats. They are averages from 338 people, so an individual could sit well above or below them. They come from a phase 2 trial, whose job is to find the dose range for larger trials, not to establish the final answer; the phase 3 programme, called TRIUMPH, is much larger and its results are what will define what retatrutide really does. And the participants were selected, trained and monitored in a way that does not resemble buying a vial and guessing. Peer-reviewed phase 3 publications are what this page will be updated from, not press releases.
Side effects recorded in the trials
The dominant side effects were gastrointestinal, exactly as with semaglutide and tirzepatide: nausea, diarrhoea, vomiting and constipation. They were mostly mild to moderate, they clustered around the dose increases, and they were more common at higher doses and with faster escalation. This is why the trials step the dose up slowly.
Beyond the gut, the trial recorded an increase in heart rate that was largest around 24 weeks and had reduced by 48, and some participants reported skin sensations, described as tingling or heightened sensitivity, which the investigators noted as a finding to watch. A minority of participants withdrew because of side effects, more so at higher doses. One participant died during the obesity trial; the published paper records the investigators' assessment of whether it was treatment-related. Either way, 338 people over 48 weeks cannot detect rare harms; that is what phase 3 and post-licensing surveillance exist for.
This is also where the difference between a licensed medicine and an unlicensed vial is starkest. Side-effect data from a trial describes a pharmaceutical-grade product at a known dose. It says nothing about what happens with a product of unknown purity, unknown concentration and unknown sterility, where the actual dose could be a fraction or a multiple of the number on the label, and where contamination adds risks the trial never had to consider.
Retatrutide pens: what they were in the trials and what they are online
In the studies, participants used pre-filled, single-dose injection devices manufactured under pharmaceutical quality control, each delivering the dose specified for that week of the protocol. The device is a delivery convenience; the drug inside, its concentration and its sterility are the substance of the thing.
Products marketed online as "retatrutide pens" or vials are unlicensed: powder of unknown origin, or pre-filled pens assembled by unknown parties from it. No retatrutide pen is licensed anywhere in the world. Whatever is written on such a pen about its contents or its dose is a claim by whoever filled it, with no regulator having checked it. That is not a legal technicality. It means the one number that matters most, how much drug is actually being delivered, is unknown.
Why there is no such thing as a retatrutide dosage guide
Every legitimate dosing schedule for a medicine comes from the same place: trials that established the dose range, a regulator that reviewed them and approved a product at specific strengths, a manufacturer that guarantees those strengths, and a prescriber who chooses within them for a particular patient and adjusts as they go. Retatrutide has the first of those, partially. It has none of the others. There is no approved strength, no licensed product and no routine prescribing route.
So the honest answer to "what is the correct retatrutide dosage" is that one does not exist yet, for anyone. The figures in this article describe what was tested and what happened; they are the raw material a regulator will eventually turn into a licensed dosing schedule. Until then, any dose you see recommended online is someone extrapolating from trial figures to a product that may not contain what it says. The lesson on how dosing protocols are structured explains in more depth why a number without its context is not information.
Regulatory status in the UK, plainly
Retatrutide has no UK marketing authorisation and none anywhere else, so there is no routine prescribing route to it in the UK outside a clinical trial. The MHRA treats products sold for people to use to modify a bodily function as medicines regardless of what the label says, and selling or advertising an unlicensed medicine is an offence for the seller. Those rules bite on the seller, but the buyer is left holding a product with no guarantee of identity, dose or sterility and nobody accountable for it.
The UK does have licensed medicines in this class, prescribed and monitored through GPs, specialist clinics and the NHS weight management pathway. Whether any of them is appropriate for a particular person is a conversation with a prescriber, who can weigh history, other medicines and goals, and who will be there if something goes wrong. Retatrutide will join that list only if phase 3 trials support it and a regulator approves it, at which point there will be a licensed dose, a licensed device and a proper answer to the question this page can only frame.
How to read the next retatrutide headline
- Check which trial it comes from, how many people it enrolled and how long it ran. A 338-person phase 2 trial and a several-thousand-person phase 3 trial are different kinds of evidence.
- Check whether the figure is an average, and whether the trial reports the spread. Averages hide the people at both ends.
- Check the dose and the schedule together. A result at 12 mg after 48 weeks of escalation says nothing about 12 mg on day one.
- Check whether the source is a peer-reviewed paper or a company announcement. Both can be accurate, but only one has been through independent scrutiny.
- Check whether side effects are reported alongside benefits. A headline that gives one without the other is marketing.
This article is educational content only and is not medical advice, diagnosis or a recommendation to use anything. Retatrutide is an unlicensed, experimental compound; the doses described are those used in monitored clinical trials and are not instructions for use. Anyone considering treatment for weight or blood sugar should speak to a GP or other qualified prescriber. Vivera Education sells nothing.
Frequently asked
- What retatrutide doses were used in the trials?
- The phase 2 obesity trial published in the New England Journal of Medicine in 2023 tested weekly injections of 1 mg, 4 mg, 8 mg and 12 mg over 48 weeks, with the higher doses reached by stepping up from 2 mg or 4 mg every four weeks. The phase 2 type 2 diabetes trial tested 0.5 mg to 12 mg weekly. These are trial doses in monitored participants, not a dosing guide.
- How is retatrutide taken?
- In the trials it was given once a week as an injection under the skin, using a pre-filled device supplied by the manufacturer, with the dose increased in steps over the first weeks to limit stomach side effects. It is an experimental medicine and has no licensed form anywhere, so there is no approved way for anyone to take it outside a clinical trial.
- How much weight did people lose on retatrutide?
- In the 48-week phase 2 obesity trial, average weight change was about 8.7% at 1 mg, 17.1% at 4 mg, 22.8% at 8 mg and 24.2% at 12 mg, against about 2.1% on placebo. Weight was still falling at 48 weeks in the higher-dose groups. These are averages from a 338-person trial; individual results varied widely and phase 3 results are what will establish the real picture.
- What are the side effects of retatrutide?
- The most common in the trials were gastrointestinal: nausea, diarrhoea, vomiting and constipation, mostly mild to moderate, mostly during the dose increases, and more frequent at higher doses. Increases in heart rate were seen, most marked around 24 weeks and lessening by 48. Some participants reported skin sensations such as tingling. A minority stopped treatment because of side effects.
- Is retatrutide approved in the UK?
- No. Retatrutide has no marketing authorisation in the UK or anywhere else and is in phase 3 trials, so there is no routine prescribing route to it outside a trial. Anything sold online as retatrutide is an unlicensed product with no regulatory check on what it contains.
- What is a retatrutide pen?
- In the trials, participants used pre-filled injection devices supplied and controlled by the manufacturer, with the dose set for each stage of the study. Nothing of that kind is licensed for sale. "Retatrutide pens" advertised online are unlicensed products filled by unknown parties, and there is no way to know whether the contents or the dose marked on them are accurate.
- Does retatrutide dose depend on body weight?
- Not in the trials. Doses were fixed amounts in milligrams for everyone in a group, regardless of body weight, and increased on a fixed schedule. Dose was chosen by the trial protocol, not calculated per kilogram.
- Where can I get help with weight in the UK?
- Through a GP or the NHS weight management pathway, which can include licensed medicines where appropriate. Licensed GLP-1 medicines exist in the UK and are prescribed and monitored by clinicians. A prescriber can discuss options; an online seller of experimental compounds cannot.
The studies and sources behind this page
Lessons on this topic
Related reading
Educational content only. Not medical advice, diagnosis or treatment. Always consult a qualified healthcare professional before changing your health regimen.